WCLC 2017

In the randomised, double-blind phase III trial PACIFIC, durvalumab has shown to improve PFS while upholding quality of life measures.

New research showed that among SCLC patients, the efficacy of using nivolumab was enhanced among those with a high TMB.

Changes in LDH above the upper limit of normal values at cycle 2 and in NLR ≥ 5 at 6 weeks predicts for disease progression.

The role of immunotherapy for patients with uncommon EGFR mutations, ROS1 and C-MET who express PD-L1 is still unclear.

Immunotherapy has differential effects at different organ sites of metastases. Nivolumab treatment appeared to be more active in immune cells (IC) rich organs.

Low/high absolute neutrophil count and high absolute eosinophil count was associated with a better outcome of nivolumab treatment.

Interferon-Gamma (IFNG) production by T-cells play a critical role in anti-cancer immune responses, a study shows.

There is a positive correlation between increasing cutpoints of PD-L1 expression and ORR and 1yr PFS, but little correlation with 1yr OS.

The 1% cut-off value for PD-L1 might become a predictive marker, expression of PD-L1 might give negative prognostics.

The expression of PD-L1 was up-regulated after neo-adjuvant chemotherapy when using 5%, 10%, 20% expression threshold.